Which is better, high‐dose metformin monotherapy or low‐dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low‐dose metformin monotherapy? A randomized, cross‐over, continuous glucose monitoring‐based pilot study

AIMS/INTRODUCTION: The present study investigated the effect of high‐dose metformin or low‐dose metformin/linagliptin combination therapy on glycemic variability (GV) in type 2 diabetes patients with insufficient glycemic control despite low‐dose metformin monotherapy in a cross‐over study using con...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Hiroshi, Nishimura, Rimei, Tsujino, Daisuke, Utsunomiya, Kazunori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497608/
https://www.ncbi.nlm.nih.gov/pubmed/30171747
http://dx.doi.org/10.1111/jdi.12922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497608/
https://www.ncbi.nlm.nih.gov/pubmed/30171747
http://dx.doi.org/10.1111/jdi.12922

Ejemplares similares